Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal eventsMitchell R. Smith, Karim Fizazi, K.N. Chi et al.|Annals of Oncology|2014Cited by 145
Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate CancerWojciech A. Cieślikowski, Andrzej Antczak, Joanna Budna et al.|Cancers|2020Cited by 41
Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate CancerWojciech A. Cieślikowski, Joanna Budna, Andrzej Antczak et al.|Journal of Personalized Medicine|2023Cited by 13